Skip to Main Content

Good morning. Elizabeth Cooney here again, subbing for the vacationing Ed Silverman as the week really gets going. Let’s have some news with our coffee.

A Covid-19 vaccine being developed by Oxford University and the drug giant AstraZeneca (AZN) generated an immune response in a study of roughly 1,000 patients, according to interim results, the first glimpse researchers have gotten at its efficacy, STAT reports. The data show a relatively safe vaccine, although side effects were greater than for a meningitis vaccine to which it was compared. AstraZeneca said it is likely that future studies will test giving patients two doses of the vaccine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!